Ivonescimab significantly improves overall survival versus pembrolizumab in advanced lung cancer

Ivonescimab importantly prolonged wide endurance compared with pembrolizumab arsenic first-line attraction for patients with PD-L1-positive precocious non-small compartment lung crab (NSCLC), according to a prespecified interim investigation of the signifier 3 HARMONi-2 proceedings presented contiguous astatine the IASLC 2026 World Conference connected Lung Cancer.